Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Completed · Phase 3
Conditions studied: Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
In brief
The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.
Key facts
- Study ID
- NCT00322556
- Run by
- CSL Behring
- People needed
- 55
- Starts
- 2005-11-01
- Expected to finish
- 2008-04-01
- Last updated by the study team
- 2012-10-26
Who can join
Age: 4 and older, up to 71. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Contact CSL Behring for facility details — Los Angeles, California, United States
- Contact CSL Behring for facility details — Centennial, Colorado, United States
- Contact CSL Behring for facility details — North Palm Beach, Florida, United States
- Contact CSL Behring for facility details — St. Petersburg, Florida, United States
- Contact CSL Behring for facility details — Fort Wayne, Indiana, United States
- Contact CSL Behring for facility details — Indianapolis, Indiana, United States
- Contact CSL Behring for facility details — Iowa City, Iowa, United States
- Contact CSL Behring for facility details — Rochester, Minnesota, United States
- Contact CSL Behring for facility details — St Louis, Missouri, United States
- Contact CSL Behring for facility details — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.